title: Clinical and endocrine aspects of treatment with ranitidine.
abstract: Ranitidine has been shown to heal the majority of duodenal ulcers during treatment with 300 or 320 mg daily for 4 to 8 weeks. Twice-daily dosage improved compliance. Subsequent maintenance treatment with ranitidinie, 150 mg at night prevented relapse in the majority of patients during 6-months' follow-up. Ranitidine did not appear to have any anti-androgenic effects.
mesh_terms: D000284:Administration, Oral; D002927:Cimetidine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005663:Furans / Q000008:administration & dosage / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011899:Ranitidine; D012008:Recurrence; D013739:Testosterone / Q000097:blood
chemical_list: D005663:Furans; D006635:Histamine H2 Antagonists; D013739:Testosterone; D002927:Cimetidine; D011899:Ranitidine; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone